Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07433673 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
A Phase 2 study of Colon and Rectal Cancer, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07433673 is a Phase 2 study of Colon and Rectal Cancer that is actively recruiting participants, run by Columbia University. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07433673, a Phase 2 study of Colon and Rectal Cancer, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
Conditions Studied
Interventions
- DRUG Cemiplimab
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-08 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07433673
The ClinicalTrials.gov registry entry for NCT07433673 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colon and Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab is the first listed.
NCT07433673 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07433673 about?
NCT07433673 is a clinical study titled "Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)". This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
What is the current status of trial NCT07433673?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-08. Estimated completion is 2029-01.
What conditions does trial NCT07433673 study?
This clinical trial studies the following conditions: Colon and Rectal Cancer.
What interventions are being tested in trial NCT07433673?
The interventions under investigation include: Cemiplimab (DRUG).
Who is sponsoring clinical trial NCT07433673?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07433673 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.